摘要
目的 检测骨桥蛋白（OPN）、CD44v6在垂体腺瘤中表达并探讨其与垂体腺瘤临床病理特征的关系.方法 应用免疫组化SP法检测80例垂体腺瘤组织中OPN和CD44v6蛋白的表达,并对二者表达与垂体腺瘤临床病理特征之间的关系进行分析.结果 OPN、CD44v6在垂体腺瘤中阳性表达率分别为66.3%、65.0%,OPN、CD44v6的表达均与患者的年龄、性别、肿瘤组织学类型无关,但在侵袭性垂体腺瘤组与非侵袭性垂体腺瘤组、复发组及非复发组之间的差异均有统计学意义（P＜0.01）,而且二者在垂体腺瘤中表达呈正相关（r=0.585,P＜0.01）.结论 OPN和CD44v6蛋白在垂体腺瘤中高表达与肿瘤侵袭性生长及复发相关,且两者在肿瘤侵袭性改变中可能起协同作用,二者联合检测有望更客观评价垂体腺瘤的侵袭性.
Objective To explore the expressions of osteopontin （OPN） and CD44v6 in pituitary adenomas and to evaluate the relationship between the expressions and invasiveness of the tumor.Methods Immunohistochemistry was used to detect the expressions of OPN and CD44v6 in 80 pituitary adenomas,and the relationships between the expressions of OPN and CD44v6 and the clinicopathologic characteristics were also analyzed.Methods The positive expression rates of OPN and CD44v6 were 66.3% and 65.0% respectively in the pituitary adenomas.Both OPN and CD44v6 expressions were different statistically in invasive group and recurrent group（P〈0.01 ）,but not correlated with patient＇ s age,sex and histological types.There was also a significantly positive relation between OPN and CD44v6 expression in pituitary adenomas （P〈0.01 ）.Conclusion The increased expressions of OPN and CD44v6 are associated with the invasiveness and recurrence of pituitary adenomas.They might have a synergetic effect in the invasive growth of the tumor,which can be taken as leading candidates for evaluating the biological behavior.
出处
《中华神经外科杂志》
CSCD
北大核心
2011年第2期152-155,共4页
Chinese Journal of Neurosurgery
基金
浙江省医药卫生科技计划项目（2007B171）
